NTLA Stock Price Today (October 2026) — Intellia Therapeutics, Inc. Analysis & Key Metrics 2026-10-07
Intellia Therapeutics, Inc. (NTLA) is trading at $11.71, down 5.34% today (as of October 2026). The stock continues to show pressure below major moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $24.00 (105.0% upside).
- Volatility is high (41.20% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: declining revenue trends (-46.20% YoY) alongside competitive pressures in the Biotechnology space.
NTLA Stock Analysis: Key Metrics & Valuation (October 2026)
Concise, actionable data for investors
Intellia Therapeutics, Inc. - Historical Price & Volume
- Price
- Volume
- Latest price
Market Cap
Enterprise Value: $1.28B
P/E Ratio
Forward P/E: N/A
Revenue Growth
Year over Year
Analyst Target
+105.0% upside potential
Key Investor Questions About NTLA
What investors need to know before buying
Based on current market data, NTLA presents a neutral technical setup with challenging fundamentals.
- Technicals say: Neutral (RSI 43.04)
- Fundamentals say: Challenging (declining revenue trends)
NTLA's growth trajectory depends on its ability to expand within the Biotechnology sector while managing margin pressures.
- Future growth will depend on performance in core Biotechnology operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for NTLA investors include debt exposure and competitive dynamics in the Biotechnology industry.
- $73.41M in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Biotechnology.
52-Week Trading Range
Over the past year, NTLA stock traded between $7.95 and $28.25 and currently trades near the low end of that range. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 41.20% annualized volatility and β=2.31, the stock exhibits high sensitivity to market moves—making NTLA suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
CRSP, NTLA, BEAM, PRME, EDIT Shares Slip — Did Claude Just Spook Gene-Editing Stocks?
CRSP shares closed down 6% on Wednesday, while PRME and EDIT stocks declined 12% and 8%, respectively.
CRISPR Therapeutics Traded Sideways and Down for 12 Months: One Wall Street Pro Expects 85% Gains Soon
CRISPR Therapeutics owns the only approved gene therapy of its kind, yet the stock sits far below where Wall Street thinks it belongs. One analyst sees a path to gains that would embarrass the broader market, but the numbers tell a complicated story.
Intellia Therapeutics (NTLA) Stock Gets FDA Priority Review For Lonvo Z Gene Editing Therapy
Intellia Therapeutics (NasdaqGM:NTLA) said the FDA accepted its Biologics License Application for lonvo-z for hereditary angioedema. The agency granted Priority Review status, positioning lonvo-z as a potential first in vivo CRISPR-based therapy in the U.S. The FDA does not plan to convene an advisory committee, with review supported by positive Phase 3 data and multiple global designations. The FDA's Priority Review of lonvo-z for hereditary angioedema is a key regulatory event to weigh...
Intellia Eyes Lonvo-z Launch as HAE PDUFA Nears, TTR Study Advances
Intellia Therapeutics (NASDAQ:NTLA) executives outlined plans for a potential launch of its hereditary angioedema treatment, lonvo-z, while discussing the company’s ongoing Phase III program in transthyretin amyloidosis and its capital position during a Morgan Stanley event. Chief Executive Officer
Can Intellia's Pipeline Progress Create Long-Term Value Amid Rivalry?
NTLA wins FDA priority review for lonvo-z, with a March 10, 2027 decision, potentially adding its first product, while nex-z studies are progressing well.
Intellia Therapeutics (NTLA) Secured a Facility for Up to $400M. Is It Worth the Cost?
Intellia Therapeutics, Inc. (NASDAQ:NTLA) entered a five-year senior secured credit facility with OrbiMed for up to $400 million and drew $75 million at closing. The remaining $325 million depends on milestones or further lender agreement. The facility bears interest at an annual rate equal to the greater of 3% or the one-month Secured Overnight Financing […]
FDA Accepts & Gives Priority Review to Intellia's BLA for HAE Drug
NTLA's BLA for lonvo-z wins FDA priority review for the treatment of HAE. A decision from the agency is expected by March 10, 2027.
3 Promising Genomics Stocks in the Spotlight in 2026
Genomics is reshaping healthcare, with WGS, NEO and NTLA advancing diagnostics and precision medicine.
Cathie Wood’s Biotech Bet Intellia Secured An FDA Priority Review For Rare Genetic Disorder Therapy – Retail Sees Upside In NTLA’s Platform
The FDA accepted Intellia’s Biologics License Application for lonvoguran Ziclumeran for Hereditary Angioedema.
Intellia Therapeutics Shares Rise as FDA Grants Priority Review to Lonvo-z
Intellia Therapeutics (NASDAQ:NTLA) shares rose 8% on Tuesday after the U. S.
Explore More Analysis for NTLA
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.
Earnings snapshot
Next report Nov 5, 2026 (before the open, usually)
Frequently Asked Questions
Common investor questions about Intellia Therapeutics, Inc.
Intellia Therapeutics, Inc. (NTLA) is currently trading at $11.71. The RSI (14-day) is at 43.0, indicating neutral territory. Wall Street analysts have a consensus "buy" recommendation. The mean analyst price target of $24.00 implies 105.0% upside from current levels. Volatility is high at 41.2% annualized, meaning significant price swings are common. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Intellia Therapeutics, Inc. (NTLA): The trailing P/E ratio is not available (the company may not be profitable). Price-to-Book is 2.28. Price-to-Sales is 27.95. Valuation should be compared to Biotechnology industry peers for context, as different sectors trade at different multiples.
Based on 17 analysts covering NTLA, the consensus price target is $24.00. This represents a 105.0% upside from the current price of $11.71. The range spans from a low target of $8.00 to a high target of $61.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Intellia Therapeutics, Inc. (NTLA) does not currently pay a regular dividend. The company may be reinvesting profits into growth initiatives, or may not yet be profitable enough to distribute earnings to shareholders.
Key risks for Intellia Therapeutics, Inc. (NTLA) investors include: 1. High volatility (41.2% annualized)—the stock can experience significant daily price swings. 2. The company is not currently profitable on a trailing basis, which creates earnings uncertainty. 3. Declining revenue (-46.2% YoY), indicating potential business headwinds. 4. Elevated short interest (42.0% of float) suggests significant bearish sentiment. 5. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 6. Biotechnology sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Intellia Therapeutics, Inc.'s (NTLA) current debt and financial health profile: Total debt stands at $73.41M. The debt-to-equity ratio is 0.10x, which is conservative and indicates a strong balance sheet with low leverage. The current ratio is 6.65, indicating strong short-term liquidity. The quick ratio is 5.61. The company holds $437.76M in cash and equivalents. Free cash flow is negative at -$249.83M, which could limit the company's ability to manage debt obligations.